Editors Note: This article discusses one or more penny stocks/microcaps. Such stocks are readily manipulated; do your own careful due diligence.

Sixty-four  (see here) of the 100 clinical-stage psychedelic drug stocks trading on North American stock exchanges research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them) and 40 of them research the treatment of illnesses based on the use of THC marijuana.

The munKNEE Psychedelic Compounds-Based Drug Stocks Index tracks 6 of the largest clinical-stage startups. They have an average market capitalization of $65.5M, ranging from $106M (Cybin) to $42.5M (Zynerba) and an average stock price of $0.69/share, ranging from $0.96 to $0.30.

Psychedelic Compounds-Based Stocks Index

The constituent performances since the end of April, YTD and from their peaks realized in 2021 are presented below in descending order:

Group 1 (market caps between US$40M and US$106M)

1. Cybin (CYBN): UP 12.1% since the end of April; (-45.8% YTD); -79.6% from its market high in 2021 
   • focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
   • Chance of Financial Distress in next 2 years: 62%
   • Analyst Consensus: 14 stock analysts currently rate CYBN as a BUY.
2. Allied Corp. (ALID): no change; (-58.8% YTD); -65.4% from its market high in 2021
   • engaged in the research, development, and production of cannabinoid health solutions in the United States and has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder
   • Chance of Financial Distress in next 2 years: 30%
   • Analyst Consensus: No analysts following ALID
3. Seelos (SEEL): no change; (-62.0% YTD); -90.2% from its market high in 2021
   • focused on developing products that address significant unmet needs in the Central Nervous System disorders and other rare disorders.
   • Chance of Financial Distress in next 2 years: 73%
   • Analyst Consensus: 12 stock analysts currently rate SEEL as a BUY.
4. Numinus (NUMIF): DOWN 17.1%; (-31.0% YTD); -80.4% from its market high in 2021 
   • provides clients with testing of controlled compounds such as LSD, ketamine, DMT, MDMA, mescaline, psilocybin and psilocin as well as conducting research of both MDMA and psilocybin to treat PTSD, depression, anxiety, and addiction.
   • Chance of Financial Distress in next 2 years: 24%
   • Analyst Consensus: No analysts following NUMIF
5. Field Trip (FTRP): DOWN 18.9%; (-65.0% YTD); -86.8% from its market high in 2021 
   • focused on building centers for psychedelic therapies across North America and Europe.
   • Chance of Financial Distress in next 2 years: 54%
   • Analyst Consensus: 10 stock analysts currently rate FTRP as a BUY.
6. Zynerba (ZYNE): DOWN 30.5%; (-66.0% YTD); -88.8% from its market high in 2021 
   • operates as a clinical stage specialty pharmaceutical company
   • Chance of Financial Distress in next 2 years: less than 2%
   • Analyst Consensus: 12 stock analysts currently rate ZYNE as a BUY.

The 6 constituents in Group 1 are DOWN 13.1% since the end of  April, on average, DOWN 60.1% YTD and -85.4% from their average market highs in 2021.

Group 2  (market caps in excess of US$300M)

Their performances are presented below in descending order from the end of April, YTD and from their peaks realized in 2021:

1. Mind Medicine (MNMD): UP 8.8% since the end of April; (DOWN 37.0% YTD); -81.4% from its market high in 2021
   • Chance of Financial Distress in the next 2 years: 58%
   • Analyst Consensus: 8 stock analysts currently rate MNMD as a BUY.
2. Atai (ATAI): DOWN 5.1%; (DOWN 46.7% YTD); DOWN 79.5% from its market high in 2021
   • Chance of Financial Distress in the next 2 years: 4%
   • Analyst Consensus: 19 stock analysts currently rate ATAI as a BUY.
3. Compass Pathways (CMPS): DOWN 7.2%; (DOWN 61.9% YTD); -82.8 from its market high in 2021
   • Chance of Financial Distress in the next 2 years: 58%
   • Analyst Consensus: 17 stock analysts currently rate CMPS as a BUY.
4. GH Resources (GHRS): DOWN 34.2%; (DOWN 58.8% YTD); -65.5% from its market high in 2021
   • Chance of Financial Distress in the next 2 years: 58%
   • Analyst Consensus: 10 stock analysts currently rate GHRS as a BUY.

The 4 constituents in Group 2 are DOWN 20.2% since the end of April, on average, DOWN 57.8% YTD and -77.4% from their average market highs in 2021.

When combined with the performance of the 6 stocks in Group 1 the category, in total, is DOWN an average of 19.2% since the end of April, DOWN 58.2% YTD and -79.1% from its average market high in 2021.